Combining magnetic nanoparticles and icosahedral boron clusters in biocompatible inorganic nanohybrids for cancer therapy

Elena Oleshkevich, Anna Morancho, Arpita Saha, Koen M.O. Galenkamp, Alba Grayston, Simonetta Geninatti Crich, Diego Alberti, Nicoletta Protti, Joan X. Comella, Francesc Teixidor, Anna Rosell, Clara Viñas

Research output: Contribution to journalArticleResearch

13 Citations (Scopus)

Abstract

© 2019 Elsevier Inc. The potential biomedical applications of the MNPs nanohybrids coated with m-carboranylphosphinate (1-MNPs) as a theranostic biomaterial for cancer therapy were tested. The cellular uptake and toxicity profile of 1-MNPs from culture media by human brain endothelial cells (hCMEC/D3) and glioblastoma multiform A172 cell line were demonstrated. Prior to testing 1-MNPs' in vitro toxicity, studies of colloidal stability of the 1-MNPs' suspension in different culture media and temperatures were carried out. TEM images and chemical titration confirmed that 1-MNPs penetrate into cells. Additionally, to explore 1-MNPs' potential use in Boron Neutron Capture Therapy (BNCT) for treating cancer locally, the presence of the m-carboranyl coordinated with the MNPs core after uptake was proven by XPS and EELS. Importantly, thermal neutrons irradiation in BNCT reduced by 2.5 the number of cultured glioblastoma cells after 1-MNP treatment, and the systemic administration of 1-MNPs in mice was well tolerated with no major signs of toxicity.
Original languageEnglish
Article number101986
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume20
DOIs
Publication statusPublished - 1 Aug 2019

Keywords

  • Boron neutron capture therapy
  • Iron oxide nanoparticles
  • m-Carboranyl
  • Nanomedicine
  • Phosphinate

Fingerprint

Dive into the research topics of 'Combining magnetic nanoparticles and icosahedral boron clusters in biocompatible inorganic nanohybrids for cancer therapy'. Together they form a unique fingerprint.

Cite this